Protagonist Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference 2026
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protagonist Therapeutics (NASDAQ:PTGX) announced that Dinesh V. Patel, Ph.D., President and CEO will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026 at 8:15 AM PST.
The company will hold one-on-one investor meetings during the conference. A live webcast is available at the provided J.P. Morgan link, and a replay will be posted on Protagonist's Investor Relations Events and Presentations webpage for one year following the event. Investors seeking meetings should contact their J.P. Morgan representative.
Details
News Market Reaction – PTGX
On Jan 7, the day this news came out, PTGX closed 0.09% above the previous close.
Data tracked by StockTitan Argus for the Jan 7 session.
Key Figures
- Conference dates
- January 12–15, 2026
- 44th Annual J.P. Morgan Healthcare Conference schedule
- Company presentation date
- January 13, 2026
- Scheduled Protagonist presentation day at J.P. Morgan conference
- Presentation time
- 8:15 AM PST
- Slot for company overview webcast
- Current price
- $82.27
- Pre-news close vs 52-week range $33.70–$96.54
- Price change 24h
- -2.27%
- Move ahead of conference participation announcement
- 52-week high discount
- -14.78%
- Distance from 52-week high of $96.54
- 200-day MA
- $62.29
- Shares trading above long-term moving average
- Market cap
- $5,262,568,764
- Equity value prior to conference news
Historical Context
-
NDA filed for rusfertide in PV with positive VERIFY Phase 3 data.
-
Q3 2025 results and broad pipeline milestones with strong cash runway.
-
Multiple rusfertide presentations at ASH highlighting Phase 3 and extension data.
-
New icotrokinra data in UC and psoriasis supporting ongoing ICONIC programs.
-
Phase 2b ANTHEM-UC results showing strong efficacy and favorable safety.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.
44th Annual J.P. Morgan Healthcare Conference - January 12-15, 2026
Format: Company Presentation
Day/Time: Tuesday, January 13 at 8:15 AM PST
If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.
A replay of the presentation will be available on the Company's Investor Relations Events and Presentations webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R"), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra's joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.